解析急性髓系白血病复杂性综述系列 - Suppr | 超能文献

Untangling Complexities of Acute Myeloid Leukemia Review Series.

作者信息

Shimony Shai, Stone Richard M

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Rabin Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

Acta Haematol. 2024;147(2):119-121. doi: 10.1159/000535574. Epub 2023 Nov 30.

DOI:10.1159/000535574

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Untangling Complexities of Acute Myeloid Leukemia Review Series.解析急性髓系白血病复杂性综述系列

Acta Haematol. 2024;147(2):119-121. doi: 10.1159/000535574. Epub 2023 Nov 30.

2

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.靶向 RNA 测序用于急性髓系白血病微小残留病的定量检测。

Haematologica. 2019 Feb;104(2):297-304. doi: 10.3324/haematol.2018.203133. Epub 2018 Aug 31.

3

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?我们距离将可测量残留病纳入急性髓系白血病的临床实践还有多远？

Haematologica. 2019 Aug;104(8):1532-1541. doi: 10.3324/haematol.2018.208454. Epub 2019 Jul 4.

4

Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.纳入可测量的（“最小”）残留病导向治疗策略以优化成人急性髓系白血病的治疗结果。

Leuk Lymphoma. 2016 Jul;57(7):1527-33. doi: 10.3109/10428194.2016.1160085.

5

Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.多参数流式细胞术检测急性白血病中的微小/可测量残留病

Curr Hematol Malig Rep. 2018 Dec;13(6):455-466. doi: 10.1007/s11899-018-0479-1.

6

Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy.造血细胞移植用于巩固治疗后仍有可测量残留病的急性髓系白血病患者的治疗。

Best Pract Res Clin Haematol. 2018 Dec;31(4):405-409. doi: 10.1016/j.beha.2018.09.009. Epub 2018 Sep 20.

7

Moving toward individualized target-based therapies in acute myeloid leukemia.迈向急性髓系白血病个体化靶向治疗。

Ann Oncol. 2023 Feb;34(2):141-151. doi: 10.1016/j.annonc.2022.11.004. Epub 2022 Nov 21.

8

Measurable residual disease testing for personalized treatment of acute myeloid leukemia.用于急性髓系白血病个体化治疗的可测量残留病检测

APMIS. 2019 May;127(5):337-351. doi: 10.1111/apm.12926. Epub 2019 Mar 28.

9

Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.基于数字液滴 PCR 的移植前 NPM1 突变负担绝对定量可预测急性髓系白血病患者的复发。

Ann Hematol. 2018 Oct;97(10):1757-1765. doi: 10.1007/s00277-018-3373-y. Epub 2018 May 22.

10

[Significance of detecting minimal/measurable residual disease utilizing genetic mutations in acute myeloid leukemia].[利用基因突变检测急性髓系白血病微小/可测量残留病的意义]

Rinsho Ketsueki. 2020;61(8):965-970. doi: 10.11406/rinketsu.61.965.

引用本文的文献

1

Cellular heterogeneity and cytokine signatures in acute myeloid leukemia: A novel prognostic model.急性髓系白血病中的细胞异质性和细胞因子特征：一种新型预后模型。

Transl Oncol. 2025 Feb;52:102194. doi: 10.1016/j.tranon.2024.102194. Epub 2024 Dec 17.